NeurAxis Publishes Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS
Portfolio Pulse from Benzinga Newsdesk
NeurAxis has published a prospective study showing that its product, IB-Stim, improves the quality of life of adolescents with Irritable Bowel Syndrome (IBS).
September 12, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeurAxis' study showing the effectiveness of IB-Stim in improving the quality of life of adolescents with IBS could potentially boost the company's reputation and sales.
The positive results from the study could increase the demand for IB-Stim, leading to increased sales and potentially a positive impact on NeurAxis' stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100